Drug intelligence / Profile preview

cerebroprotein hydrolysate for injection (III)

Development stage
Unknown
Lead developer
ShanXi PuDe Pharmaceutical
Modality
Peptides
Administration
Intravenous
01

Overview

**Cerebroprotein hydrolysate for injection (III)** is a Chinese-approved, porcine brain tissue-derived neurotrophic peptide and amino-acid hydrolysate product. It is supplied as a lyophilized powder for intravenous reconstitution and contains a heterogeneous mixture of low-molecular-weight peptides and free amino acids rather than a single molecular entity. The product is intended for cerebrovascular and brain-injury-related neurological conditions, including stroke-related cerebrovascular disease and traumatic brain injury. Its pharmacology is described as neurotrophic and neuroprotective: it is proposed to support neuronal metabolism, neuronal survival and differentiation, synaptic plasticity, and protection from ischemic or neurotoxic injury; however, it has no established single molecular target. Shanxi Pude Pharma markets 30 mg and 60 mg presentations, measured by total nitrogen content.

Brand names
古立西
Other names
Cerebroprotein Hydrolysate Injection III注射用脑蛋白水解物(III)
02

Targets

GFRA1 (Glial cell line-derived neurotrophic factor family receptor alpha 1)CNTFR (Ciliary neurotrophic factor receptor alpha subunit-lif receptor beta Subunit-gp130 complex)NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on cerebroprotein hydrolysate for injection (III).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cerebroprotein hydrolysate for injection (III).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call